Abstract
Despite recent progress in the treatment of acute myelogenous leukemia (AML), most patients who achieve complete remission (CR) relapse within 2 years following induction chemotherapy. In some of these latter patients (40%–70%), especially when the duration of first complete remission has been longer than 18 months, a second complete remission may be obtained using different salvage chemotherapeutic regimens. High-dose cytosine arabinoside (HD ARA-C) either alone or in combination with other drugs such as intercalating agents are commonly used in such situations. Once a second CR is achieved, its duration is usually short and does not exceed 1 year in most patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amadori S, Meloni G, Petti MC, Papa G, Miniero R, Mandelli F (1989) Phase II trial of intermediate dose ARA-C (IDAC) with sequential Mitoxantrone ( MITOX) in acute myelogenous leukemia. Leukemia 3: 112–114
Bortin MM, Gale RP, Kay HEM, Rimm AA (1983) For the Advisory Committee of the International Bone Marrow Transplant Registry. Bone marrow transplantation for acute myelogenous leukemia. JAMA 249: 1166–1175
Gorin NC, Herve P, Aegerter P, Goldstone A, Linch D, Maraninchi D, Burnett A, Helbig W, Meloni G, Verdonck LF, De Witte T, Rizzoli V, Carella A, Parlier Y, Auvert B, Goldman J (1986) For the Working Party on Autologous Bone Marrow Transplantation of the European Bone Marrow Transplantation Group (EBMTG). Autologous bone marrow transplantation for acute leukemia in remission. Br J Haematol 64: 385–395
Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, Facon T, Dufour P, Ifrah N (1989) For the French Study Group of Idarubicin Leukemia. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cyta-rabine. J Clin Oncol 7: 45–49
Heinemann V, Jehn U (1990) Rationales of a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cyto-sine arabinoside. Leukemia 4: 790–796
Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Planker M, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Buchner T (1987) High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14 [Suppl 1]: 73–77
Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hustein W (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia. An active and well-tolerated regimen. J Clin Oncol 6: 213–217
Marit G, Cony P, Duclos F, Puntous M, Broustet A, Reiffers J (1990) Treatment of relapsed or refractory acute leukemia: comparison of two different regimens. Haematol Blood Transfus 33: 614–617
Reiffers J, Castaigne S, Tilly H, Lepage E, Leverger G, Henon P, Douay L (1987) Hematopoietic reconstitution after autologous blood stem cell transplantation: a report of 46 cases. Plasma Ther Transfus Technol 8: 360–362
Reiffers J, Leverger G, Marit G, Castaigne S, Tilly H, Lepage E, Henon P, Douay L, Troussard X for the France Auto Greffe Group (1989) Haematopoietic reconstitution after autologous blood stem cell transplantation. In: Gale RP, Champlin RE (eds) Bone marrow transplantation: current contro versis. Liss, New York, pp 313–320
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Reiffers, J., Marit, G., Cony-Makhoul, P., Faberes, C., Fernandez, P., Broustet, A. (1992). Possible Effect of Autologous Blood Stem Cell Transplantation on Outcome of Acute Myeloid Leukemia in First Relapse. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_88
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_88
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive